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Abstract: Posterior cortical atrophy (PCA) is a neurodegenerative syndrome characterized by predominant
visual deficits and parieto-occipital atrophy, and is typically associated with Alzheimer’s disease (AD)
pathology. In AD, assessment of hippocampal atrophy is widely used in diagnosis, research, and clinical
trials; its utility in PCA remains unclear. Given the posterior emphasis of PCA, we hypothesized that hippo-
campal shape measures may give additional group differentiation information compared with whole-
hippocampal volume assessments. We investigated hippocampal volume and shape in subjects with PCA
(n5 47), typical AD (n5 29), and controls (n5 48). Hippocampi were outlined on MRI scans and their 3D
meshes were generated. We compared hippocampal volume and shape between disease groups. Mean
adjusted hippocampal volumes were 8% smaller in PCA subjects (P< 0.001) and ~22% smaller in tAD sub-
ject (P< 0.001) compared with controls. Significant inward deformations in the superior hippocampal tail
were observed in PCA compared with controls even after adjustment for hippocampal volume. Inward
deformations in large areas of the hippocampus were seen in tAD subjects compared with controls and PCA
subjects, but only localized shape differences remained after adjusting for hippocampal volume. The shape
differences observed, even allowing for volume differences, suggest that PCA and tAD are each associated
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INTRODUCTION
Posterior cortical atrophy (PCA) is a clinicoradiological
syndrome characterized by impairment of visuoperceptual,
visuospatial, and other posterior cognitive functions and
atrophy of the occipital, parietal, and occipito-temporal
cortices [Benson et al., 1988; Crutch et al., 2012]. PCA is
most commonly caused by Alzheimer’s disease (AD)
[Alladi et al., 2007; Renner et al., 2004; Tang-Wai et al.,
2004] and is probably the most common atypical clinical
presentation of AD [Dubois et al., 2014]. Although AD is
the most common underlying pathology in PCA (>80%)
[Alladi et al., 2007; Renner et al., 2004; Tang-Wai et al.,
2004] a number of cases have other underlying pathologies
such as dementia with Lewy bodies (DLB), corticobasal
degeneration, prion disease, and subcortical gliosis [Crutch
et al., 2012]. Unlike typical AD (tAD), where memory loss
is one of the earliest and most prominent symptoms, epi-
sodic memory function in PCA is initially relatively well
preserved [Mendez et al., 2002; Tang-Wai et al., 2004].
The hippocampus, known to play an important role in
the formation of long-term, consciously accessible memo-
ries [Mayes et al., 2007; Squire et al., 2007], is one of the
earliest structures to atrophy in tAD. Recently, hippocam-
pal atrophy, visually or volumetrically assessed using
magnetic resonance imaging, has been included in diag-
nostic criteria for AD [Dubois et al., 2007; Hyman et al.,
2012]. In addition, lower hippocampal volumes have been
proposed as an enrichment strategy to select individuals at
risk of developing clinical AD for trials of putative treat-
ments [Hill et al., 2014]. Further, change in hippocampal
volume is widely used as a biomarker in AD clinical trials
[Fox et al., 2005].
Previous whole-brain cross-sectional MRI studies (which
used voxel-based morphometry to compare gray matter vol-
ume differences and FreeSurfer to compare cortical thick-
ness) have shown distinct atrophy patterns in subjects with
PCA as compared to tAD with PCA showing greater atrophy
in the right occipital cortex [Whitwell et al., 2007] and in the
posterior parietal cortex (most markedly in the right posterior
parietal cortex) [Lehmann et al., 2011] compared with tAD
subjects and tAD subjects showing greater atrophy in the left
medial temporal lobe compared to PCA [Lehmann et al.,
2011; Whitwell et al., 2007]. A reduction in gray matter vol-
ume was observed in the right hippocampus in PCA as com-
pared with controls using voxel-based morphometry
[Whitwell et al., 2007]. However there has been no study to
date that has specifically assessed hippocampal volume and/
or shape differences in PCA subjects as compared with con-
trols and tAD subjects. Evaluating the extent to which the
hippocampus is affected in PCA may contribute to efforts to
improve our understanding of the factors driving phenotypic
heterogeneity in AD. More practically, the value of bio-
markers such as hippocampal atrophy may also differ in
PCA compared with typical AD, and have a bearing upon
the question of whether to include individuals with PCA in
clinical trials in which study outcome measures have been
selected for patients with more typical amnestic or global
clinical presentations [Crutch et al., 2012].
In this study, we aimed to: investigate hippocampal vol-
ume differences between PCA, tAD, and healthy controls;
localize areas of hippocampal tissue loss; and investigate
whether shape metrics give any additional group separa-
tion information above volume alone.
METHODS
Subjects
One hundred twenty-four subjects were identified retro-
spectively from a clinical database at the Dementia Research
Centre (PCA (n5 47), tAD (n5 29), and control subjects
(n5 48)). All subjects have been described in a previous
study of gray matter volume and cortical thickness in PCA
and tAD [Lehmann et al., 2011]. Subjects required at least
one T1 weighted volumetric MRI scan to be included in the
study. All PCA patients fulfilled the clinical criteria for PCA
proposed by Mendez et al. [2002] and Tang-Wai et al. [2004]
and more recently by Dubois et al., [2014] criteria for atypi-
cal AD, including evidence of posterior cortical dysfunction
on neuropsychological assessment and atrophy on MRI. In
addition, subjects were only included in the PCA group if
there was no indication of another underlying pathology
(such as DLB). Although the neuropsychological tests com-
pleted were not identical across all individuals, all PCA
patients showed evidence of deficits (scored <5th percen-
tile) in at least two tasks sensitive to parietal dysfunction—
object perception (VOSP Object Decision test [Warrington
and James, 1991a,b]), spelling (Graded Difficulty Spelling
test [Baxter and Warrington, 1994]), space perception (VOSP
Number Location test [Warrington and James, 1991b]), and
calculation (Graded Difficulty Arithmetic test [Jackson and
Warrington, 1986])—and had relatively preserved episodic
memory (>5th percentile on verbal and or visual
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Recognition Memory Tests [Warrington, 1984, 1996]). Those
included in the tAD group fulfilled revised NINCDS-
ADRDA criteria for probable AD [Dubois et al., 2007;
McKhann et al., 1984] and had significant episodic memory
impairments (namely gradual and progressive change in
memory function, objective evidence of significantly
impaired episodic memory, and presence of medial tempo-
ral lobe atrophy) with episodic memory impairments quan-
tified as performance <5th percentile on the verbal and
visual Recognition Memory Tests [Warrington, 1984, 1996]).
Image Acquisition
T1 weighted volumetric MR scans were acquired for all
subjects on 1.5 T Signa scanners (General Electric, Milwau-
kee). All scans used an inversion recovery sequence and
all but 7 of the scans consisted of 124 contiguous 1.5 mm
coronal slices through the head. The remaining 7 consisted
of 120 contiguous 1.5 mm coronal slices (5 PCA subjects
and 2 tAD subjects). Since this was a retrospective cohort,
there was some variation in the scan parameters and in-
plane resolutions of the MRI scans; See Table I for a break-
down of the imaging parameters by diagnostic group. The
majority of subjects in each diagnostic group had an in-
plane resolution of 0.9 mm 3 0.9 mm (including all 7 sub-
jects with 120 coronal slices).
Image Processing
Brain, hippocampal, and total-intracranial volume
extraction
In-house segmentations software [Freeborough et al.,
1997] was used to segment whole-brains and hippocampi.
Whole-brain regions were segmented in native space
using a semi-automated technique [Freeborough et al.,
1997] and were manually edited where necessary. These
whole brain regions were used to generate a volume, and
also to use in the subsequent registration step.
The MRI scans were then aligned to MNI space and
resampled to produce isotropic voxels of 1 mm 3 1 mm 3
1 mm. The left and right hippocampi were manually seg-
mented by experienced image analysts. The hippocampi
were manually delineated using every coronal slice refer-
encing a standard neuroanatomical atlas [Duvernoy, 2005]
using a protocol that was largely similar to the EADC-
ADNI Harmonized Hippocampal Protocol (HarP) [Boc-
cardi et al., 2015]. Our protocol includes the head, body,
and full extent of the hippocampal tail. Two key differen-
ces between our protocol and HarP were (1) we excluded
the white matter that separates the lateral ventricles from
the gray matter of the hippocampus at the level of the hip-
pocampal tail and (2) we excluded vertical digitations
from the hippocampal head. In addition, we used a mini-
mum threshold of 70% of the mean whole brain intensity
(using the whole brain region transformed into MNI
space) to determine the boundary between the CSF and
hippocampus for improved consistency.
Estimated total intracranial volume (eTIV) was meas-
ured using Freesurfer [Buckner et al., 2004].
Hippocampal Shape Analysis
The hippocampal regions generated by manual segmenta-
tion were used to analyze differences in shape between the
subject groups. In this study, we used spherical harmonic
(SPHARM) decomposition to represent hippocampal shape.
Arbitrarily shaped but simply connected objects can be
decomposed into a weighted series of SPHARM basis func-
tions. SPHARM shape decompositions have the advantage of
encapsulating both global and local shape features compactly.
The SPHARM-PDM (Spherical Harmonics-Point Distribution
Model) toolbox was used to calculate the coefficients of the
SPHARM basis functions of the hippocampi [Styner et al.,
2006]. For a more detailed description of the SPHARM proc-
essing steps used in this study see Appendix A.
Statistics: Demographics
We compared age (at the time of the scan) between the
diagnostic groups using linear regression analysis with
TABLE I. MRI scan parameters by diagnostic group
MRI parameters Controlsa (n5 48) PCA (n5 47) tAD (n5 29)
FOV (mm) 240–280 200–280 200–280
TR (ms) 11.7–15 11.7–15 13.6–15
TE (ms) 4.2–5.4 4.2–6.4 4.2–5.4
TI (ms) 650 650 650
Flip angle (degree) 13–20 13–20 15–20
% Phase FOV 75–100 75–100 75–100
Slice thickness (mm) 1.5 1.5 1.5
No. of subjects by in-plane resolution (mm) 0.9 3 0.9 35 31 21
1.1 3 1.1 4 1 3
0.8 3 1.0 7 14 5
0.8 3 1.3 0 1 0
aScan parameters not available for 2 subjects.
r Differential Hippocampal Shapes in Posterior Cortical Atrophy Patients r
r 3 r
age as the dependent variable and diagnostic group (PCA,
tAD, or controls) as the independent variable. Fishers
exact test was used to compare the gender distributions
between the groups. An unpaired t-test was used to com-
pare Mini-Mental State Examination (MMSE) scores
between tAD and PCA subjects. All analyses were per-
formed in Stata 12.0.
Statistics: Brain and Hippocampal Volume
Analyses
We compared whole brain and hippocampal volumes
between the diagnostic groups using linear regression
analyses. Brain or hippocampal volume was the depend-
ent variable, diagnostic group (PCA, tAD or controls) was
the independent variable, and we adjusted for mean-
centered age, gender, and mean-centered head size. All
analyses were performed in Stata 12.0.
Statistics: Hippocampal Shape Analysis
We used the SurfStat toolbox for Matlab to perform sta-
tistical comparisons on the hippocampal shapes [Worsley
et al., 2009]. We performed two analyses on the hippocam-
pal shapes. In the first analysis, the distance between the
surface of individual meshes and the mean mesh was the
dependent variable, group was the independent variable
and we adjusted for mean-centered age, gender, and
mean-centered head size. This was in order to visualize
whether there were any shape or volume differences in
PCA subjects as compared to controls and tAD. The sec-
ond analysis was like the first analysis, but we adjusted
for mean-centered hippocampal volume, instead of mean-
centered head size. This was in order to visualize shape
differences that were not due to volume differences. We
ran additional analyses adjusting for mean-centered
MMSE score and mean-centered disease duration as well
as mean-centered age, gender, and mean-centered head
size for the PCA vs. tAD comparisons in order to deter-
mine whether the differences observed in these compari-
sons were independent of these measures of disease
severity. All comparisons were corrected for multiple com-
parisons (family-wise error FWE correction). Maps show-
ing where there were significant differences in
hippocampal surface morphology were generated along
with effect size maps.
Classification of Subjects Using Hippocampal
Shape Features
To quantify the extent to which hippocampal shape dif-
ferences described group differences, we used soft-margin
support vector machines (SVMs) [Cortes and Vapnik,
1995]. The python package sci-kit learn was used for this
purpose [Pedregosa et al., 2011]. Since we were interested
in whether SPHARM coefficients were better able to dis-
tinguish groups than hippocampal volume alone we used
two SVMs for each group-wise comparison, one with the
SPHARM coefficients as features and the other using just
the left and right hippocampal volumes as features. Each
subject had a total of 1,014 SPHARM coefficients (from
both the left and right hippocampi) since we used decom-
position up to degree 12 (see Appendix A). A nested
cross-validation approach was taken and is described in
detail in Appendix B.
RESULTS
Participant Demographics
A total of 124 subjects were included in this study.
See Table II for a summary of participant demographics.
The mean age of tAD subjects was higher by approxi-
mately 5 years than in controls and PCA subjects
(P< 0.02 in both comparisons). The mean MMSE scores
was lower in tAD subjects than PCA subjects (P5 0.01).
There was no difference in disease duration or gender
distributions between the diagnostic groups (P> 0.4,
both tests).
Brain and Hippocampal Volume Analysis
Both PCA subjects and tAD subjects had significantly
smaller mean adjusted brain volumes than the controls
(P< 0.001) but there was no significant difference in mean
adjusted brain volume between the PCA subjects and the
tADs (P5 0.3). PCA subjects were found to have signifi-
cantly smaller mean adjusted hippocampal volumes on
both the right and left sides as compared to controls
(P 0.002, both comparisons) (see Table III). They were
however significantly larger than those seen in tAD sub-
jects (P 0.001, both comparisons).
Hippocampal Shape Analysis
Comparison of PCA and controls
Significant differences in surface morphology were seen
between PCA subjects and controls when adjusting for
TABLE II. Participant demographics
Controls
(n5 48)
PCA
(n5 47)
Typical AD
(n5 29) P-value
Age (years) 63.6 (9.7) 63.0 (7.0) 68.3 (8.4) 0.02a
% Male 31% 40% 45% 0.5b
MMSE score/30 N/A 21.2 (4.6) 18.3 (4.5) 0.01c
Disease duration (years) N/A 4.9 (2.7) 5.3 (3.1) 0.6c
aRegression analysis.
bFisher’s Exact Test.
cUnpaired t-test.
Mean (SD) unless otherwise stated.
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age, gender, and head size: these were largely confined to
the posterior hippocampus with inward deformations in
the hippocampal tail region on both the right and left
sides of the PCA subjects compared to controls (see the
blue regions in Fig. 1a). Significant inward deformations
remained in the hippocampal tail regions of PCA subjects
when adjusting for hippocampal volume rather than head
size effectively identifying areas of focal loss or deforma-
tion over and above the global hippocampal volume loss
(see blue regions in Fig. 2a).
Comparison of PCA and tAD
Outward deformations in the mean right and left hippo-
campal surfaces of PCA subjects were seen compared with
tAD in large areas across the whole of the hippocampus
(see yellow/red regions in Fig. 1c). There were only very
small regions where the mean surface of the tAD subjects
had a significant outward deformation compared to PCA
(see blue regions in Fig. 1c). When adjusting for hippocam-
pal volume rather than TIV no significant differences
remained on the right side but significant differences in
hippocampal shape were still seen in the left hippocampus
in the left superior body with PCA outwardly deformed
compared to tAD (see Fig. 2c). The hippocampal shape dif-
ferences observed between PCA and tAD subjects appear
to be independent of disease severity as adjusting for
MMSE score and disease duration made very little differ-
ence to the deformation patterns observed (see Fig. 3).
Comparison of tAD and Controls
In tAD, large areas of the mean left and right hippocam-
pal surfaces were inwardly deformed as compared to con-
trols when adjusting for age, gender, and head size (see
Fig. 1b). The mean tAD hippocampal surface was
inwardly deformed with respect to controls in most areas
(see the blue regions in Fig. 1b) with some small regions
where there was an outward deformation of the mean sur-
face in tAD compared to controls (see the red/yellow
regions in Fig. 1b). When adjusted for hippocampal vol-
ume however, only a small region of significant difference
survived in the superior medial left hippocampal tail (see
Fig. 2b) and there were no significant differences on the
right side.
Disease Classification Using SPHARM
Coefficients
The accuracies, sensitivities, specificities, mean AUCs,
f-scores for each of the SVMs are shown in Table IV. In
the PCA–control comparison, by using SPHARM coeffi-
cients only we were able to achieve a classification accu-
racy of 77% compared to 56% when using hippocampal
volume information alone. McNemar’s test showed that
the SVM classifier using SPHARM coefficients significantly
outperformed the classifier using hippocampal volumes
(P5 0.002). In the controls–tAD and PCA–tAD compari-
sons, hippocampal volume alone was able to classify sub-
jects as accurately as the SPHARM coefficients.
DISCUSSION
PCA subjects had significantly reduced (8% lower) mean
adjusted hippocampal volumes (adjusted for age, gender
and head size) compared to controls; it is interesting to
note that the PCA subjects had relatively preserved epi-
sodic memory function despite this volume loss. The
shape analyses pointed to the differences in surface mor-
phology in PCA being relatively localized posteriorly with
inward deformations seen in the hippocampal tail regions
in comparison with controls.
The loss of hippocampal volume in PCA was much
lower than that seen in typical amnestic AD (25% smaller
hippocampi than controls). PCA subjects had significantly
larger hippocampal volumes than tAD subjects and that
was reflected in the shape differences reported. When
adjusting for age, gender, and head size, large areas of
outward deformations, likely representing regions of rela-
tively preserved hippocampal tissue, were found in PCA
subjects compared to tAD; these were mostly seen in the
superior hippocampal body with some more minor differ-
ences in the tail and the head portion of the subiculum.
When we adjusted for hippocampal volume rather than
head size, we still saw some significant shape differences
in PCA subjects as compared to tAD (PCA>tAD) over a
TABLE III. Brain and hippocampal volumes (adjusted for age, gender and head-size)
Controls (n5 48) PCA (n5 47) Typical AD (n5 29)
Mean adjusted brain volume (cm3) 1131.7 [1111.5, 1151.9] 1005.8a [9851.0, 1026.5] 1021.9a [9957.5, 1048.1]
Mean adjusted left hippocampal volume (cm3) 3.2 [3.1, 3.3] 3.0a [2.8, 3.1] 2.5a,b [2.3, 2.6]
Mean adjusted right hippocampal volume (cm3) 3.3 [3.2, 3.4] 3.0a [2.9, 3.2] 2.6a,b [2.4, 2.7]
aP 0.001 as compared with controls.
bP5 0.000 as compared with PCA.
Mean [Confidence Interval]
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Figure 1.
Hippocampal shape difference after adjusting for age, gender,
and TIV in (a) PCA vs. controls, (b) tAD vs. Controls, (c) PCA
vs. tAD. The color scale for statistical difference represents the
FWE-error corrected P-values at a threshold of P5 0.05. Blue
indicates areas where there was an inward deformation in (a)
PCA as compared to tAD, (b) tAD as compared to controls, (c)
PCA as compared to tAD whereas red/yellow indicates areas
where there was an outward deformation. A5 anterior,
P5 Posterior. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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Figure 2.
Hippocampal shape difference after adjusting for age, gender,
and hippocampal volume in (a) PCA vs. controls, (b) tAD vs.
Controls, (c) PCA vs. tAD. The color scale for statistical differ-
ence represents the FWE-error corrected P-values at a thresh-
old of P5 0.05. Blue indicates areas where there was an inward
deformation in (a) PCA as compared to tAD, (b) tAD as com-
pared to controls, (c) PCA as compared to tAD whereas red/
yellow indicates areas where there was an outward deformation.
A5 anterior, P5 Posterior. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
r Differential Hippocampal Shapes in Posterior Cortical Atrophy Patients r
r 7 r
small area in the left hippocampus. Given that the major-
ity of difference was removed by adjusting for hippocam-
pal volume it is unsurprising that SPHARM coefficients
did not aid in the classification of PCA subjects from tAD.
To our knowledge, this is the first study to report shape
differences in the hippocampi of PCA subjects. These
results suggest that although the hippocampi in PCA sub-
jects are relatively preserved as compared to tAD, there is
some tissue loss occurring in the hippocampi of PCA sub-
jects compared with controls. The tissue loss appears to be
most significant in the superior lateral hippocampal tail
region, fitting with the posterior pattern (or gradient) of
atrophy seen in these subjects. In addition, when adjusting
for hippocampal volume, significant differences in surface
morphology were still seen in PCA subjects. Consistent
with this, the hippocampal SPHARM coefficients were bet-
ter able to classify PCA subjects from controls than volume
alone. Taken together these data indicate that there is a
distortion of the shape of the hippocampi in PCA, which
could be due to focal atrophy in the hippocampus as well
as the tissue to which it is connected. Although the exact
functional organization of the hippocampus remains
unclear, it has been suggested that the posterior hippo-
campus supports detailed, context-rich spatial [Hirshhorn
et al., 2012] and autobiographical [Addis et al., 2004] mem-
ories, whilst the anterior hippocampus supports more
“gist”-like memories [Strange et al., 2014]). To date there
has been no detailed characterization of memory function
in PCA, but the present findings of a posterior–anterior
gradient of hippocampal volume loss and shape change
may predict qualitative as well as quantitative distinctions
between memory processes in PCA and tAD.
Figure 3.
Hippocampal shape difference in PCA vs. tAD after adjusting for
(a) age, gender, MMSE score, disease duration, and head size
and (b) age, gender, MMSE score, disease duration, and hippo-
campal volume. The color scale for statistical difference repre-
sents the FWE-error corrected P-values at a threshold of
P5 0.05. Blue indicates areas where there was an inward defor-
mation in PCA as compared to tAD whereas red/yellow indi-
cates areas where there was an outward deformation.
A5 anterior, P5 Posterior. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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As expected, we found significantly reduced hippocam-
pal volumes in the tAD subjects as compared to controls:
widespread significant inward deformations were seen
across large areas of both the right and left hippocampi in
tAD. Although it is difficult to precisely locate these
inward deformations with respect to hippocampal sub-
fields, in tAD these seem to approximate to the CA1 sub-
field as well as the anterior and posterior subiculum. A
number of previous studies have compared hippocampal
shapes in tAD and controls [Gerardin et al., 2009; Li et al.,
2007; Lindberg et al., 2012; Shen et al., 2012; Thompson
et al., 2004]. Our findings are in keeping with two previ-
ous studies that found inward deformations in tAD sub-
jects across large areas of the both the left and right
hippocampi [Gerardin et al., 2009; Shen et al., 2012]. One
study found large areas of inward deformations on the left
hippocampus, particularly in the hippocampal head as
well as the superior tail region but found no differences in
the right hippocampus [Li et al., 2007]; another study
reported localized inwards deformations in the hippocam-
pal head in tAD subjects, particularly on the left side
[Thompson et al., 2004] whilst another study found some
inward deformations in the body of the left hippocampus
and a small area of inward deformation on the medial
part of the right hippocampal head [Lindberg et al., 2012].
Differences in the numbers of subjects, disease severities,
shape analysis methods, and hippocampal segmentation
methods used may account for some of the different find-
ings in these studies. When adjusting for hippocampal vol-
ume, we found no significant differences in shape on the
right hippocampus and only a small region in the superior
medial portion of the hippocampal tail on the left hippo-
campus. One other study [Shen et al., 2012] also investi-
gated shape differences where the effect of volume was
removed and, as in our study, found significant shape dif-
ferences in the posterior hippocampus. The fact that most
of the differences in shape were removed when adjusting
for hippocampal volume suggests that in tAD there was
generalized, diffuse tissue loss across the whole of the hip-
pocampus. Indeed, we found that in this comparison, the
SPHARM coefficients did not aid in the classification of
tAD subjects from controls.
The fact that shape metrics helped separate PCA patients
from controls suggests that they may be useful in addition to
volume and could be explored in other diseases where diag-
nosis is difficult and subtle differences in atrophy patterns
exist. In this study, shape metrics were no better than hippo-
campal volumes at distinguishing tAD subjects from con-
trols. However, it is possible that the hippocampus does not
atrophy uniformly during the tAD disease course. Indeed,
previous studies have shown that the CA1 subfield is dispro-
portionately affected in early AD [Chetelat et al., 2008; Cser-
nansky et al., 2005; La Joie et al., 2013; Mueller et al., 2010;
Pluta et al., 2012; Wang et al., 2006] and that hippocampal
subfields or hippocampal shape may be more sensitive at dis-
tinguishing MCI or very mild AD subjects from controls than
whole-hippocampal volume [Csernansky et al., 2005; La Joie
et al., 2013; Mueller et al., 2010; Pluta et al., 2012]. Therefore,
SPHARM coefficients may prove to be more useful at distin-
guishing controls from tAD at an earlier disease stage.
This study has a number of strengths. First, the hippo-
campi were segmented manually, including the full extent
of the structure from tail to head. Secondly, although PCA
is an atypical variant of AD, we had a reasonable number
of cases to include in our analyses. The mean MMSE score
was lower in the tAD subjects than in the PCA subjects,
this reflects the weighting of the questions toward memory
and orientation and the relative lack of questions relating
the visual deficits experienced by PCA subjects. Brain vol-
umes in the PCA and tAD subjects were not significantly
different however suggesting similar levels of overall brain
atrophy between the groups. Future studies with more
detailed neuropsychological testing are required to investi-
gate the inevitably complex relationship between clinical
phenotype, cognition, and hippocampal shape and volume.
There were several limitations to this study that warrant
discussion. First, the SPHARM-PDM pipeline requires that
the shapes being analyzed have spherical topology. In the
case of one of the hippocampi from one of the subjects
with tAD, the SPHARM-PDM processing failed, perhaps
because this hippocampus did not have spherical topology
(this subject was therefore excluded from all analyses and
from the demographics table). It could be that the failure
rate is higher when comparing subjects with particularly
pronounced atrophy or by use of automated techniques
where borders of the hippocampal masks may not adhere
to the spherical topological description. Secondly, we
applied some smoothing to the segmented regions before
TABLE IV. Comparison of performance of SVM classifier using SPHARM coefficients vs SVM classifier using left and
right hippocampal volumes as features
SVM features Sensitivity Specificity Accuracy Mean AUC f-score P-value (McNemar’s test)
PCA vs. Controls SPHARM coefficients only 0.74 0.80 0.77 0.84 0.76 0.002
Hippocampal volumes only 0.59 0.55 0.56 0.57 0.56
PCA vs. tAD SPHARM coefficients only 0.68 0.82 0.77 0.82 0.69 0.819
Hippocampal volumes only 0.67 0.81 0.76 0.83 0.67
Controls vs. tAD SPHARM coefficients only 0.77 0.91 0.86 0.93 0.80 0.763
Hippocampal volumes only 0.77 0.94 0.87 0.91 0.81
P-values are from McNemar’s test.
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the spherical parameterization. Therefore, it may be that
some of the differences that do in fact exist are not found
using this method since they have been attenuated.
Thirdly, pathological confirmation of AD was only avail-
able in five of the PCA subjects and it may be that some
of the remaining PCA subjects actually have a different
underlying disease [Crutch et al., 2012]. Fourthly, the type
of registration is an important consideration in interpreting
the results regarding localization of tissue loss in any com-
parison. Other registration methods may align hippocampi
differently and therefore localize deformations in other
areas. Fifthly, the MRI scans used in this study were from
a retrospective cohort with some variety in the scan
parameters and in-plane resolutions; ideally, all subjects
would have identical imaging parameters. Although we
do not believe that this would materially affect the results
presented here, we cannot exclude this as a possibility and
further studies using consistent imaging parameters would
be required to confirm our findings. Sixthly, the images
used were of limited resolution compared with the high-
resolution temporal lobe imaging which is achievable
[Winterburn et al., 2013]. Given that the hippocampi are
relatively small structures it may be that using higher
resolution scans would enable the detection of more subtle
shape differences between groups. Finally, caution is
required when interpreting the results from shape analysis
studies—a recent study indicated that the SPHARM-PDM
method of shape analysis might overestimate regions of
significant difference [Gao et al., 2014]. We used stringent
statistical methods (family-wise error correction) in order
to minimize false detection of differences where there
were in fact none.
In conclusion, the hippocampal region is affected in
PCA at a relatively earlier stage of the disease when mem-
ory is relatively preserved and produces posterior shape
changes. We found reduced hippocampal volumes in PCA
subjects as compared to controls—intermediate between
controls and tAD. Whereas the macroscopic differences
between tAD and control subjects were governed by vol-
ume rather than shape, as were the differences between
PCA and tAD, most of the differences between PCA and
controls are governed by shape differences (PCA smaller
in the tail). This was further evidenced by shape
(SPHARM) coefficients that were better able to distinguish
healthy controls from PCA subjects than hippocampal vol-
ume alone suggesting that shape metrics are important
descriptors of hippocampal differences in PCA as com-
pared with controls.
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APPENDIX A: SPHARM PROCESSING STEPS
Any structure with spherical topology can be repre-
sented by a weighted sum of spherical harmonic
(SPHARM) functions. For a perfect representation of the
original shape an infinite number of SPHARM basis func-
tions would be required. In practice, the number of
SPHARM basis functions used to represent the original
shape is determined by a user-defined parameter “Lmax,”
the maximum degree of the SPHARM expansion. The
greater Lmax is, more basis functions will be used in the
representation and the finer the surface representation
becomes. We chose to set Lmax5 12 as we felt that this
provided a sufficient amount of detail.
The processing steps were as follows:
1. The hippocampi, that had been manually segmented
in MNI space at an isotropic resolution of 1 mm,
were binarized and resampled to an isotropic resolu-
tion of 0.5 mm. Interior holes were filled and a mini-
mal smoothing operation was applied to ensure
spherical topology (Fig. A1a). As described by Styner
et al. [2006], the smoothing was a two-step process:
first a binary closing operation was applied followed
by anti-aliasing smoothing. The anti-aliasing smooth-
ing operation used in the SPHARM-PDM package
(ITK filter itk::AntiAliasBinaryImageFilter) smooths
out jagged boundaries but uses the original binary
surface as a constraint ensuring minimal loss in detail
or structure (the smoothed surface is guaranteed to
be within6 3 voxels of the original surface) [Whi-
taker, 2000].
2. These pre-processed binary segmentations were then
transformed into raw surface meshes and spherical
parameterizations for each of the hippocampal
meshes were computed (Fig. A1b).
3. From the raw surface meshes and their spherical
parameterizations, SPHARM (spherical harmonic)
descriptions were computed and corresponding trian-
gulated surface meshes were generated (Fig. A1c).
These were all visually checked against the original
manual segmentations to ensure that the segmenta-
tions were well represented by their SPHARM
decompositions.
4. The triangulated surface meshes were then aligned to
one (randomly selected) individual’s hippocampal
mesh using Procrustes alignment (translation and rota-
tion only) and the triangulated surface meshes were
then regenerated such that the vertices corresponded
between each individual’s mesh and the chosen refer-
ence mesh of the single subject (Fig. A1d). This was
done for left and right sides separately.
5. A mean mesh was calculated from the aligned
meshes (including the individual reference mesh
used for alignment in the previous step) and the
meshes were then aligned to the mean mesh using
Procrustes alignment and again the individual
meshes were regenerated such that the vertices corre-
sponded between this mean mesh and each subject’s
meshes. Again, this was done for the left and right
sides separately.
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6. The meshes were loaded up side by side and the
alignment was visually checked for alignment
failures.
7. Finally, the triangulated surfaces meshes were con-
verted from VTK format to MNI object format and
imported into Matlab.
APPENDIX B: CLASSIFICATION OF SUBJECTS
USING HIPPOCAMPAL SHAPE FEATURES
A nested cross-validation approach was taken whereby
the sample was split into 10 mutually exclusive stratified
sets of approximately equal size. Figure B1 summarizes
the nested cross-validation process used. The classifier
was trained and evaluated 10 times, once with each of the
folds (data splits) as the test set and the remaining data
used for training. In order to determine the best kernel
(linear or radial basis function (RBF)) and kernel parame-
ters, we used grid search and stratified 10-fold cross-vali-
dation (experimental evidence suggests 10-fold cross-
validation is the best method for model selection [Kohavi,
1995 ]) on the training data each time. This sample split-
ting for kernel parameter choice was performed in order
to avoid over-fitting the data. Once the kernel and hyper-
parameters were tuned, the resulting SVM was fitted to
the training data. Finally, the SVM was used to predict the
labels of the test set on which the SVM was not trained.
This process was repeated for each of the 10 folds. We
used the same folds for the SVM with SPHARM coeffi-
cients as features and for the SVM with hippocampal vol-
umes as features in order to be able to make comparisons.
The accuracy (proportion of correctly classified subjects),
sensitivity (proportion of true positives), and specificity
(proportion of true negatives) were then calculated. We
also chose to report the area under the ROC curve (AUC)
and f-score statistics since they both have advantages over
accuracy when assessing the performance of a classifier.
The AUC takes into account the decision value of the clas-
sifier which accuracy ignores. The f-score is appropriate
for imbalanced classes (where one class is under-
represented compared to another) and so is a better mea-
sure of the performance of a classifier than accuracy.
Accuracy, sensitivity, and specificity are the same whether
computing across all folds or whether taking the average
of each of the folds. The AUC and f-measure are different
however when computing across all folds or when averag-
ing over the folds. Previous work suggests that taking the
mean AUC of each of the cross-validation folds and com-
puting the f-score across all folds (as opposed to averag-
ing) are less biased [Forman and Scholz, 2010]. Therefore,
mean AUC and f-score over all folds are reported in this
study. Finally, in order to determine whether the SVM
using the SPHARM coefficients was significantly better or
worse at classification than the SVM using hippocampal
Figure A1.
Summary of shape analysis procedure: (a) Hippocampi are seg-
mented, holes filled and minimal smoothing applied, (b) raw sur-
face meshes generated and spherical parameterizations are
computed, (c) triangulated surface meshes are computed from
spherical parameterizations, (d) surface meshes aligned (transla-
tion and rotation), (e) distance between mean mesh and individ-
ual meshes at each vertice is calculated, (f) statistical
comparisons performed. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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volumes as features, we used the McNemar test [McNe-
mar, 1947] since it has been shown to have a low type-1
error [Dietterich, 1998].
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